Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
|
|
Loxo Oncology, Inc. (LOXO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/08/2018 |
8-K
| Quarterly results |
| 08/09/2018 |
8-K
| Quarterly results |
| 05/08/2018 |
8-K
| Quarterly results |
| 03/01/2018 |
8-K
| Quarterly results |
| 11/02/2017 |
8-K
| Quarterly results |
| 08/08/2017 |
8-K
| Quarterly results |
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 03/07/2017 |
8-K
| Form 8-K - Current report |
| 11/02/2016 |
8-K
| Form 8-K - Current report |
| 08/03/2016 |
8-K
| Form 8-K - Current report |
| 05/04/2016 |
8-K
| Quarterly results|
Docs:
|
"Loxo Oncology Announces First Quarter 2016 Financial Results STAMFORD, Conn., May 4, 2016 — Loxo Oncology, Inc. , a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported financial results for the first quarter ended March 31, 2016. Loxo Oncology will not be conducting a conference call in conjunction with this earnings release. “With cash runway well into 2018, we are nicely positioned to bring our programs through new and meaningful milestones,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “In the first half of 2016, we were able to show continued and durable efficacy for LOXO-101 in TRK fusion cancer patients as part of our Phase 1 update at AACR. For the remainder of the yea..." |
|
| 03/15/2016 |
8-K
| Quarterly results |
|
|